Nanologica Q4 2023: Weak sales and EBIT – strong outlook - Redeye

Redeye continue to see an exciting case in Nanologica despite the Q4 report falling short of sales and EBIT estimates, with write-downs impacting the results. We maintain a positive outlook as follow-up orders are poised to generate considerable sales in the quarters ahead, the company targets SEK100m in 2024 sales.

Länk till analysen i sin helhet: https://www.redeye.se/research/974342/nanologica-q4-2023-weak-sales-and-ebit-strong-outlook?utm_source=finwire&utm_medium=RSS